Am J Psychiatry 161:1642-1649, September 2004
© 2004 American Psychiatric Association
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Christer Allgulander, M.D.,
Alv A. Dahl, M.D.,
Carol Austin, M.D.,
Philip L.P. Morris, M.D., Ph.D.,
Jesper A. Sogaard, M.D.,
Rana Fayyad, Ph.D.,
Stan P. Kutcher, M.D., and
Cathryn M. Clary, M.D.
OBJECTIVE: Sertraline’s efficacy and tolerability in treating generalized anxiety disorder were evaluated. METHOD: Adult outpatients with DSM-IV generalized anxiety disorder and a total score of 18 or higher on the Hamilton Anxiety Rating Scale were eligible. After a 1-week single-blind placebo lead-in, patients were randomly assigned to 12 weeks of double-blind treatment with placebo (N=188, mean baseline anxiety score=25) or flexible doses (50–150 mg/day) of sertraline (N=182, mean anxiety score=25). The primary outcome measure was baseline-to-endpoint change in the Hamilton anxiety scale total score. A secondary efficacy measure was the Clinical Global Impression (CGI) improvement score; response was defined as a score of 2 or less. RESULTS: Sertraline patients had significantly greater improvement than placebo patients on all efficacy measures at week 4. Analysis of covariance of the intent-to-treat group at endpoint (with the last observation carried forward) showed a significant difference in the decrease from baseline of the least-square mean total score on the Hamilton anxiety scale between sertraline (mean=11.7) and placebo (mean=8.0). Significantly greater endpoint improvement with sertraline than placebo was obtained for mean scores on the Hamilton anxiety scale psychic factor (6.7 versus 4.1) and somatic factor (5.0 versus 3.9). The rate of responders, based on CGI improvement and last observation carried forward, was significantly higher for sertraline (63%) than placebo (37%). Sertraline was well tolerated; 8% of patients versus 10% for placebo dropped out because of adverse events. CONCLUSIONS: Sertraline appears to be efficacious and well tolerated in the treatment of generalized anxiety disorder.
This article has been cited by other articles:
|
|
|
|
 
M. Pollack, G. Kinrys, A. Krystal, W. V. McCall, T. Roth, K. Schaefer, R. Rubens, J. Roach, H. Huang, and R. Krishnan
Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder
Arch Gen Psychiatry,
May 1, 2008;
65(5):
551 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson
An effect-size analysis of pharmacologic treatments for generalized anxiety disorder
J Psychopharmacol,
November 1, 2007;
21(8):
864 - 872.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Rynn, M. A. Riddle, P. P. Yeung, and N. R. Kunz
Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials
Am J Psychiatry,
February 1, 2007;
164(2):
290 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Baldwin, A. K. T. Huusom, and E. Maehlum
Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study
The British Journal of Psychiatry,
September 1, 2006;
189(3):
264 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al.
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
November 1, 2005;
19(6):
567 - 596.
[Abstract]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
